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Researchers in the BUSM Department of Anatomy are discovering new 
connections between brain injury and behavior. Their findings are lead-
ing to Improved diagnosis and, perhaps, treatment for people with mem-
ory disorders. See story on page 3. 
Research and clinical work with the tunable laser by Oon Tian Tan, M.D., promises to 
revolutionize the treatment of certain portwine stains. (Photo by Bradford F. Herzog) 
Gallstone research raises possibility 
of new therapies, preventive methods 
New tunable laser 
greatly improves 
treatment of certain 
facial birthmarks 
A new type of laser that dramatically 
improves the treatment of certain 
facial birthmarks and that also may 
have far-ranging applications in other 
medical specialties is being devel-
oped by researchers in the Depart-
ment of Dermatology at Boston Uni-
versity School of Medicine. A 
sophisticated way of delivering 
energy, lasers currently are being 
used by physicians for such diverse 
purposes as burning away atheros-
clerotic buildup, tumors or disfiguring 
birthmarks. 
Oon Tian Tan, M.D., an assistant 
professor of dermatology at BUSM 
and a University Hospital clinician, is 
studying the use of a tunable dye 
laser to treat portwine stains (PWS). 
Her clinical results indicate that it is 
possible to target the laser beam in 
blood vessels so that the surround-
ing tissues remain undamaged. 
Portwine stains are vascular birth-
marks, very often on the face, which 
progress from a flat, pale pinkish-red 
in children to a raised, deep red-pur-
ple in adults. The color is the result 
of abnormally dilated vessels scat-
tered mainly throughout the dermis, 
the layer just below the surface of 
the skin. Heat from the laser 
destroys these vessels, thus reduc-
ing discoloration of the skin. 
For several years, dermatologists 
continued on page 2 
New research into the origins and 
structure of gallstones has raised the 
prospect of both new preventive 
techniques and new, nonsurgical 
treatments for the painful accretions. 
Heading the group at Boston Uni-
versity School of Medicine investigat-
ing gallstones is J. Thomas LaMont, 
M.D., a professor of medicine and 
chief of the Section of Gastroenterol-
ogy at University Hospital. According 
to LaMont, there is at present no 
convenient and effective medical 
treatment for gallstones. As a result, 
most patients whose gallstones pro-
duce clinical symptoms—the most 
common being abdominal pain—are 
treated surgically. An estimated half 
million cholecystectomies, or gall-
stone operations, are performed in 
the United States each year. 
Now, however, basic research by 
LaMont and his colleagues is unveil-
ing features of gallstones that show 
promise of producing both preventive 
strategies and new types of non-
surgical treatments. The group cur-
rently is experimenting with both pre-
ventive and therapeutic agents. 
continued on page 5 
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Laser advances... 
continued from page 1 
have used two other types of lasers 
to treat portwine stains but these 
devices frequently caused scarring, 
especially in young children and fair-
skinned patients. Tan's laser, which 
uses organic dyes to "tune" the light 
beam to a specific wavelength, 
appears to be an improvement over 
alternative PWS laser treatments. 
According to Tan, the CO2 laser 
results in a fair-to-poor response in 
27 percent of patients and produces 
extensive, disfiguring scarring in 
about 9 percent of patients. More 
recently, the blue-green argon laser 
has been the standard treatment for 
PWS. Although the argon laser is 
successful in the majority of cases, 
about 30 percent of patients suffer 
permanent, unsightly scars when 
energy spreads from the vessels and 
burns surrounding cells. 
"These lasers act like a blow 
torch," said Tan. "They actually cook 
the tissue." By contrast, she added, 
the tunable dye laser is like a micro-
wave, passing through tissue that 
doesn't contain blood and diffusing 
outward from the blood vessels. 
"Because the damage induced by 
the dye laser is so specific, we don't 
have to give any local anesthesia 
and no post-treatment wound care is 
required." 
Tan's work with a tunable dye 
laser allowed her to precisely control 
the wavelength used. For her studies 
on the treatment of portwine stains, 
she chose a wavelength of 577 
nanometers (nm) because it coin-
cides with one of the three absorp-
tion peaks of oxyhemoglobin in red 
blood cells. This results in the laser 
energy being concentrated within 
vessels while sparing the surround-
ing tissue from unnecessary damage. 
Other types of lasers damage skin 
from the beam's point of contact 
down to the depth of penetration, 
producing a coagulated block of tis-
sue that subsequently dies and heals 
Section of skin after application of laser pulse 
stiows coagulation In blood vessels (dark 
clumps at center) but no damage to 
surrounding cells or epidermal layer. (Pfioto 
courtesy of Oon Tian Tan, M.D.) 
with scarring. The 577 nm laser, 
however, causes coagulation only of 
red blood cells. 
Tan began treating portwine stain 
patients two years ago using an opti-
cally-pumped Candela model LFDL6 
tunable dye laser with a yellow rho-
damine 575 dye, operated at a 
wavelength of 577 nm. The first 
group of 50 pilot-study patients, 
whose ages range from 3 to 69 
years, now are completing treatment. 
Reporting on her research. Tan 
observed, "The epidermis is totally 
intact; no hairs are destroyed. The 
elasticity and the skin markings of 
the treated area remain normal. And, 
there are no pigmentary abnormali-
ties in fair Caucasian skin. In other 
words, the skin remains normal; only 
the redness in the PWS area prior to 
treatment disappears." 
In addition to controlling the wave-
length more precisely. Tan also 
releases the laser beam in a single 
pulse rather than in a continuous 
stream as is done with the argon and 
CO2 lasers. "We chose a pulse dura-
tion of 300 micro-seconds because it 
matches the thermal-relaxation time 
of the blood vessels," added Tan. 
Thermal-relaxation time is the time 
required for a target to cool from the 
temperature immediately following 
the laser pulse to half that value. In 
this way, heat energy concentrates 
within the vessel without dissipating. 
A third aspect Tan is investigating 
in connection with the tunable laser 
is dosage, which she determines by 
doing a test on normal skin. "Our 
rationale has been to find out the 
dose that induces purpura, the red 
spot that appears within 10 minutes 
of laser radiation and doesn't blanch. 
This is the threshold dose," she 
explained. 
The portwine stain is treated with 
twice the threshold dose of normal 
skin. A typical PWS area, such as 
half an adult forehead, generally 
requires from four to six treatments 
over the period of a year. 
"We've basically dealt with the 
parameters that are important to 
laser selectivity," Tan said. "I think 
we ought to look at using the laser in 
a much more sophisticated way, 
using all of its parameters." 
Tan, whose studies have been 
funded in part by the Dermatology 
Foundation and the Arthur O. and 
Gullam M. Wellman Foundation, 
believes that the days of lasers' 
indiscriminate damage to tissue are 
limited. "Not doing unnecessary dam-
age is very important," she said. "We 
coined the term 'selective photother-
molysis' to describe this fine-tuning 
ability." 
Tan has been working in collabora-
tion with Carl Franzblau, Ph.D., 
chairman of the Department of Bio-
chemistry at BUSM; A.J. Walsh, 
Ph.D., a professor of electrical engi-
neering at the University of Texas at 
Austin; and Stephen Kennedy, M.Sc, 
a physicist at BUSM. 
—Shirley B. Moskow 
Suggested Further Readings 
1. Tan, O.T. et al: Histologic responses of port-
wine stains treated by argon, carbon diox-
ide and tunable dye lasers: A preliminary 
report. Arch Dermatol, (in press.) 
2. Morelli, J . et al: Tunable dye laser (577 nm) 
treatment of portwine stains. Laser Surg 
Med. 6: 1-94, 1986. 
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Mapping the brain: Researchers develop 
models of how disease impairs memory 
Researchers in the Department of 
Anatomy at Boston University School 
of Medicine are mapping out areas 
of the brain believed to be behind a 
number of memory dysfunctions, 
including those that afflict people 
with Alzheimer's disease, Hunting-
ton's disease and alcoholic Korsak-
off's syndrome. 
By developing a model in the Rhe-
sus monkey, Douglas Rosene, Ph.D., 
an associate professor of anatomy, 
and Mark Moss, Ph.D., an assistant 
research professor of anatomy, seek 
to understand how different parts of 
the brain responsible for memory 
communicate with each other and 
with the rest of the cerebral cortex, 
where most of the analysis of mem-
ory is carried out. 
Their research has a dual focus. 
One approach is based on purely 
anatomical studies of how the brain 
is assembled. Rosene and Moss are 
studying the limbic system, which 
includes such brain structures as the 
hippocampus, the amygdala and the 
basal forebrain. Attention to these 
associated areas makes sense, the 
researchers said, not only because 
studies in animals have shown that 
these areas are involved in memory, 
but also because they are affected in 
certain neurological diseases that are 
characterized by memory problems. 
Rosene and Moss believe the 
structures of the limbic system work 
as an integrated unit along with the 
cerebral cortex in the storage of 
memory, and consequently, when 
one part breaks down, the system as 
a whole fails. 
The goal of their anatomical stud-
ies is to map out the relationship 
among the areas in the limbic sys-
tem. To do this the researchers use 
a variety of tracer dyes that are 
injected into the brain, taken up by 
neurons and transported along their 
axons. Where these tracers end up 
identifies the neuronal pathways 
between brain regions. 
In one type of experiment, three 
different-colored fluorescent tracers 
are injected into different parts of the 
brain thought to receive axons from 
the hippocampus. These retrograde 
types of tracers flow backward along 
axons into the neurons of the hippo-
campus. Analysis of brain sections 
then provides a color-coded chart of 
the routes that messages travel from 
specific hippocampal neurons to 
other locations in the brain. The 
presence of two or three dyes within 
the same neuron identifies those that 
send branching axons, and hence 
identical information, to two or three 
areas of the brain. With this tech-
nique Rosene and Moss recently 
have demonstrated that individual 
neurons of the basal forebrain have 
connections both to the orbital frontal 
cortex and the medial dorsal thala-
mus. This discovery is significant in 
light of the second focus of their 
research: correlated behavioral and 
anatomical studies involving the 
basal forebrain. 
According to Rosene, "We have 
seen in monkeys that damage to the 
basal forebrain produces memory 
dysfunction less severe but similar to 
that seen in Alzheimer's patients. 
Understanding the anatomy of the 
connections of the basal forebrain 
can lead to functional hypotheses 
about how structures work together 
in the storage of learned information." 
The investigators are testing their 
hypotheses in the laboratory to 
develop a primate model of Alzhei-
mer's disease. In addition, Rosene 
and Moss are collaborating on 
behavioral and anatomical studies of 
normal aging in monkeys and 
humans that may help clinicians 
identify a patient's memory disorder 
sooner. 
In developing a primate model of 
Alzheimer's disease, the researchers 
can control the location of the lesion 
to produce a behavior similar to the 
human disorder. "In these studies, 
we make small, discrete lesions in 
Douglas Rosene, Ph.D., right, and Mark Moss, Ph.D., discuss Images of brain showing locations 
of tracer dyes. (Photo by Bradford F. Herzog) 
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Graph compares ability of 
normal Rhesus monkeys 
and those with basal 
forebrain lesions to recall 
Information learned prior 
to the Injury. Brain-injured 
monkeys show 
significantly less ability to 
recall recently learned 
Information, but performed 
equally well on tasks 
Involving older memory. 
Asterisks indicate 
statistical significance. 
(Graph courtesy of 
Douglas Rosene, Ph.D., 
and Mark Moss, Ph.D.) 
parts of the limbic system of anes-
thetized Rhesus monkeys and then 
test their cognitive function using a 
battery of learning and memory 
tasks. In the Delayed Recognition 
Span Task, the animal is shown a 
board with several objects on it. The 
board is then hidden from the ani-
mal's view and a new object is 
added. The board is uncovered and 
the monkey must identify the new, 
unfamiliar object in order to be 
rewarded. The procedure is repeated 
until the monkey makes a mistake. 
Adapted for use with human 
patients, this game-like recognition 
test has proved useful to clinicians in 
identifying Alzheimer's disease, par-
ticularly in its early stages, and also 
in differentiating Alzheimer's from 
other age-related cognitive disorders 
that may appear similar at first. 
The tests, developed by Moss, 
also may provide a means of charac-
terizing brain structures involved in 
the beginning of the disease and 
those involved in later stages. The 
tests already are being used by 
researchers at University Hospital at 
Boston University Medical Center 
and at other institutions across the 
country, helping physicians to differ-
entiate Alzheimer's disease from 
other amnestic or dementing ill-
nesses. In its early stages Alzhei-
mer's disease can be particularly dif-
ficult for clinicians to differentiate 
from depression. On the Delayed 
Recognition Span Task, however, the 
pattern of performance by patients 
with Alzheimer's disease and by 
those with depression is quite differ-
ent. 
A recent report by Moss and col-
leagues at other institutions pub-
lished in the Archives of Neurology 
contains the results of a study com-
paring test scores of normal subjects 
with groups of patients having 
Alzheimer's, Huntington's or Korsak-
off's disorders. One finding was the 
dramatic differences in the patterns 
of memory loss of people in these 
groups. Alzheimer's patients are dis-
tinguished by a much more rapid 
rate of forgetting than patients with 
the other conditions. Conversely, 
patients with Korsakoff's syndrome 
or Huntington's disease, although 
they have difficulty in learning new 
things, have a normal rate of forget-
ting; they lose about the same per-
centage of information as a normal 
person would over the same time. 
One additional finding was that Hun-
tington's patients appear to have bet-
ter memory for verbal information 
over visual information. 
The challenge now for Rosene and 
Moss is to tie together the findings 
from the anatomical studies and the 
behavioral tests. For the past few 
years, attention has been focused on 
the basal forebrain as the key struc-
ture involved in memory deficits. 
"However, we recently discovered 
that the basal forebrain may not be 
as critical for short-term memory 
function as originally thought. Dam-
age to the basal forebrain alone in 
monkeys does not produce the dra-
matic memory deficit that is seen in 
Alzheimer's patients," said Moss. 
The conflict over the role of the 
basal forebrain may stem from the 
type of memory that is studied. 
Rosene and Moss distinguish 
between new learning (anterograde 
memory) and learning that occurred 
before the onset of the disease 
(retrograde memory). Evidence sug-
gests that while the basal forebrain 
may not be involved in anterograde 
memory, it may be important in retro-
grade memory. Thus, the short-term 
memory dysfunction that usually 
appears as the first symptom of 
Alzheimer's disease may be due to 
structures outside the basal fore-
brain. However, the difficulty patients 
eventually have with older memo-
ries—for example, their childhood— 
may be more directly due to involve-
ment of the basal forebrain. 
Funding for Rosene and Moss's 
research is provided by grants from 
the National Institute on Aging and 
the National Institute of Neurological 
and Communicative Disorders and 
Stroke. 
—Caroline H. Lupfer 
Suggested Further Readings 
1. Moss, Mark B.: Differential patterns of 
memory loss among patients with Alzhei-
mer's disease, Huntington's disease and 
alcoholic Korsakoff's syndrome. Arch of 
Neurol. 43: 239-246, 1986. 
2. Albert, M.S. and Moss, Mark B.: The 
Assessment of Memory Disorders in 
Patients with Alzheimer's Disease. Neurop-
sychology of Memory. Squire, L R . and But-
ters, N. eds. Guilford Press, 1984. 
3. Kemper, Thomas L.: Neuroanatomical and 
Neuropathological Changes in Normal 
Aging and Dementia. Clincial Neurology of 
Aging. Albert, M.L ed. Oxford Press, 1984. 
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Gallstone research... 
continued from page 1 
"We're still at a very early point in 
our studies, but the results we've 
had so far in both areas are encour-
aging," said LaMont. 
The primary role of the gallbladder, 
which is located just under the liver, 
is to store and then discharge the 
bile produced in the liver. The bile 
goes into the small intestine, where it 
breaks down fatty foods and thus 
makes them digestible. 
By far the most common form of 
gallstones are those created mainly 
from cholesterol. The stones are 
found only in cultures that have diets 
relatively rich in cholesterol. An esti-
mated 20 million Americans have 
gallstones, though in many cases 
there are no symptoms. 
When LaMont and his associates 
began their investigations, they knew 
from previous studies that gallstone 
formation is associated with gallblad-
der stasis—a condition in which the 
organ's normal tendency to contract 
is markedly reduced. 
"There are a number of factors— 
pregnancy, prolonged intravenous 
feeding, fasting, birth-control medica-
tions—that produce stasis of the gall-
bladder," said LaMont. "These condi-
tions are all associated with 
gallstones, and it has been shown 
that stasis is common to all of them." 
From the work of Donald M. Small, 
M.D., a professor of medicine and 
biochemistry and director of BUSM's 
Biophysics Institute, LaMont's group 
also knew that the bile must be 
supersaturated with cholesterol in 
order for gallstones to form. They 
also discovered, however, that super-
saturation, even in combination with 
gallbladder stasis, is not enough to 
cause stones. In fact, supersatura-
tion is a common condition in cul-
tures with cholesterol-rich diets, and 
seems to occur as often in individu-
als unaffected by stones as in gall-
stone sufferers. 
In their quest for answers as to 
what else besides stasis and super-
saturation might be involved in the 
formation of gallstones, the research-
ers focused their attention on the 
mucus secreted by the gallbladder. 
The investigators were especially 
interested in the protein mucin, the 
main component of mucus. 
In laboratory experiments, LaMont's 
group showed that hypersecretion of 
mucin by the gallbladder is a neces-
sary precursor of gallstones. Accord-
ing to Bernard F. Smith, M.D., an 
assistant professor of medicine and 
an associate of LaMont's, hyperse-
cretion combined with stasis pro-
Some samples of human gallstones. (Photo 
by Bradford F. Herzog) 
duces a sharply increased risk that 
gallstones will form. 
"When the mucus is secreted into 
the bile, it begins to accumulate as a 
gel," said Smith. "If the gallbladder 
was contracting avidly and forcing 
everything out, then even if you were 
secreting excessive amounts of 
mucus it wouldn't matter, because 
the mucus would be flushed down-
stream. But with stasis, the gel 
remains in the gallbladder." 
The investigators have found that 
the gel becomes linked with bilirubin, 
a breakdown product of hemoglobin 
and the substance that gives bile its 
greenish tint. 
The mucus-bilirubin combination is 
described as a pigmented sludge. 
This sludge provides a binding sur-
face for cholesterol, and mucin 
appears to be the key factor in the 
binding process. "Mucin is a long 
molecule that's shaped something 
like a bottle brush," said LaMont. 
"There's a protein core, and 'bristles' 
that are made out of sugars." Various 
J. Thomas LaMont, M.D. and associate Bernard F. Smith, M.D., left, discuss data on the 
molecular character of mucin. (Photo by Bradford F. Herzog) 
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A cross-section of a fiuman gallstone displays 
layers of accretion. (Pfioto by Bradford F. 
Herzog) 
points along the core are free of bris-
tles, he added, and these points 
serve as binding sites for the choles-
terol-bilirubin compound. 
The group does not know what 
makes the soft compound harden 
into gallstones. Identifying mucin as 
a key component of the stones, how-
ever, has aided the investigators in 
targeting their search for preventive 
techniques and treatments. 
The secretion of mucin appears to 
be triggered by prostaglandins, hor-
mone-like substances that are pro-
duced in many different types of tis-
sues. In experiments with prairie 
dogs, which normally have little cho-
lesterol in their bile, the investigators 
showed that aspirin's well-known 
ability to inhibit prostaglandins can 
be harnessed to prevent gallstones. 
One group of animals was fed a 
cholesterol-free diet, a second 
received a high-cholesterol diet, and 
a third was given cholesterol accom-
panied by aspirin. "The animals who 
were fed high-cholesterol diets and 
no aspirin all developed stones," 
noted LaMont, "but none of those 
who were given aspirin got stones." 
With further confirmation, the find-
ing may someday yield an approach 
for preventing gallstones in high-risk 
populations. Meanwhile, LaMont's 
group continues to explore potential 
new treatments for stones. 
"From a therapeutic point of view, 
the key point about cholesterol gall-
stones is that they contain more than 
just cholesterol," said LaMont. "They 
have a matrix, which is made out of 
mucin and probably some other pro-
teins. We have to attack that matrix 
as well as the cholesterol." 
As a result, the group has been 
experimenting with a combination of 
two types of agents: a compound 
which dissolves the cholesterol, and 
an agent known as Muco-mist, which 
is used to treat mucus buildups in 
asthmatics. Tests of the combined 
agents in vitro showed that they 
could dissolve gallstones within two 
or three days. 
Since the agents under study are 
established medications, and since 
both are known to reach the gallblad-
der when administered orally, the 
prospects for a useful therapy seem 
promising. LaMont emphasized, how-
ever, that a lot more lab work must 
be done before clinical trials can be 
considered. 
"The next step is to design a deliv-
ery system for these agents," he 
noted. "We'll probably start by 
implanting human gallstones in labo-
ratory animals so we can determine 
the best way to administer the 
agents and dissolve the stones." 
Lament and Smith's gallstone 
research is supported by funds from 
the National Institutes of Health. 
—Richard P. Anthony 
Suggested Further Readings 
1. Smith, B.F. and Lament, J.T.: The patho-
genesis of gallstones. Hospital Practice, 
December 1984, 93-104. 
2. Smith, B.F. and Lament J.T.: Hydrophobic 
binding properties of bovine gallbladder 
mucin. J Biol Chem. 259: 12170-12177, 
1984. 
3. Smith, B.F. and Lament J.T.: Identification 
of gallbladder mucin-bilirubin complex in 
human cholesterol gallstones: Effects of 
reducing agents on in-vitro dissolution of 
matrix and intact gallstones. J Clin Investi-
gation 76: 439-445, 1985. 
4. Smith, B.F. and Lament, J.T.: The central 
issue of cholesterol gallstones. Hepatology 
6: 529-531, 1986. 
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